Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kyndryl Holdings Inc (KD) vs Smith & Nephew plc (SNN) Price & Performance

Kyndryl Holdings IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Kyndryl Holdings Inc vs Smith & Nephew plc — how do they compare? Kyndryl Holdings Inc trades at $13.26 (market cap $2.97B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Smith & Nephew plc is far larger — about 4.2× Kyndryl Holdings Inc's market cap, and Smith & Nephew plc pays a 2.64% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.

KDSNN
Market Cap
$2.97B$12.50B
Sector
TechnologyHealth
52-Week High
$33.14$38.70
52-Week Low
$10.59$28.73
Enterprise Value
$5.79B$15.53B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kyndryl Holdings Inc

Kyndryl (KD) trades at $14.02, showing modest daily gains of 0.21%. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, the company achieved profitability in 2025 with $252M net income after three years of losses, though revenue declined to $15.1B. Recent developments include the planned acquisition of Healthcare IT Leaders to boost AI capabilities and Q1 2027 results showing a $0.12 per share loss on $3.6B revenue.

While Kyndryl demonstrates improving profitability and strategic AI investments, investors face mixed signals with analyst consensus leaning hold (71%) and revenue declines. The stock trades near analyst targets with upside limited to technical momentum. Key risks include ongoing revenue pressure and the integration challenges of recent acquisitions.

Smith & Nephew plc

SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.

The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kyndryl Holdings Inc

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.

Read more on KD

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN